151 related articles for article (PubMed ID: 14618683)
1. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex.
Lacroix LP; Dawson LA; Hagan JJ; Heidbreder CA
Synapse; 2004 Feb; 51(2):158-64. PubMed ID: 14618683
[TBL] [Abstract][Full Text] [Related]
2. The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus.
Dawson LA; Nguyen HQ; Li P
Neuropsychopharmacology; 2001 Nov; 25(5):662-8. PubMed ID: 11682249
[TBL] [Abstract][Full Text] [Related]
3. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
[TBL] [Abstract][Full Text] [Related]
4. Effects of 5-HT(6) receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat.
Dawson LA; Li P
J Neural Transm (Vienna); 2003 Jun; 110(6):577-90. PubMed ID: 12768354
[TBL] [Abstract][Full Text] [Related]
5. Effects of the 5-HT
Mørk A; Russell RV; de Jong IE; Smagin G
Eur J Pharmacol; 2017 Mar; 799():1-6. PubMed ID: 28188762
[TBL] [Abstract][Full Text] [Related]
6. In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate.
Dawson LA; Nguyen HQ; Li P
Br J Pharmacol; 2000 May; 130(1):23-6. PubMed ID: 10780993
[TBL] [Abstract][Full Text] [Related]
7. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Li Z; Ichikawa J; Huang M; Prus AJ; Dai J; Meltzer HY
Psychopharmacology (Berl); 2005 Dec; 183(2):144-53. PubMed ID: 16220333
[TBL] [Abstract][Full Text] [Related]
8. R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study.
Koch S; Perry KW; Nelson DL; Conway RG; Threlkeld PG; Bymaster FP
Neuropsychopharmacology; 2002 Dec; 27(6):949-59. PubMed ID: 12464452
[TBL] [Abstract][Full Text] [Related]
9. A microdialysis study of ST1936, a novel 5-HT6 receptor agonist.
Valentini V; Frau R; Bordi F; Borsini F; Di Chiara G
Neuropharmacology; 2011 Mar; 60(4):602-8. PubMed ID: 21185318
[TBL] [Abstract][Full Text] [Related]
10. In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.
Leggio GM; Cathala A; Neny M; Rouge-Pont F; Drago F; Piazza PV; Spampinato U
J Neurochem; 2009 Oct; 111(2):614-23. PubMed ID: 19702657
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of amphetamine-induced changes in dopamine and 5-HT by a 5-HT(6) receptor antagonist.
Dawson LA; Nguyen HQ; Li P
Brain Res Bull; 2003 Feb; 59(6):513-21. PubMed ID: 12576149
[TBL] [Abstract][Full Text] [Related]
12. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models.
Hirst WD; Stean TO; Rogers DC; Sunter D; Pugh P; Moss SF; Bromidge SM; Riley G; Smith DR; Bartlett S; Heidbreder CA; Atkins AR; Lacroix LP; Dawson LA; Foley AG; Regan CM; Upton N
Eur J Pharmacol; 2006 Dec; 553(1-3):109-19. PubMed ID: 17069795
[TBL] [Abstract][Full Text] [Related]
13. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine.
Jordan S; Kramer GL; Zukas PK; Moeller M; Petty F
Synapse; 1994 Dec; 18(4):294-7. PubMed ID: 7886621
[TBL] [Abstract][Full Text] [Related]
14. Effect of metyrapone on the fluoxetine-induced change in extracellular dopamine, serotonin and their metabolites in the rat frontal cortex.
Rogóż Z; Gołembiowska K
Pharmacol Rep; 2010; 62(6):1015-22. PubMed ID: 21273658
[TBL] [Abstract][Full Text] [Related]
15. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.
Koch S; Hemrick-Luecke SK; Thompson LK; Evans DC; Threlkeld PG; Nelson DL; Perry KW; Bymaster FP
Neuropharmacology; 2003 Dec; 45(7):935-44. PubMed ID: 14573386
[TBL] [Abstract][Full Text] [Related]
16. Central administration of NPY or an NPY-Y5 selective agonist increase in vivo extracellular monoamine levels in mesocorticolimbic projecting areas.
Quarta D; Leslie CP; Carletti R; Valerio E; Caberlotto L
Neuropharmacology; 2011; 60(2-3):328-35. PubMed ID: 20868698
[TBL] [Abstract][Full Text] [Related]
17. Effects of acute and chronic buspirone on impulsive choice and efflux of 5-HT and dopamine in hippocampus, nucleus accumbens and prefrontal cortex.
Liu YP; Wilkinson LS; Robbins TW
Psychopharmacology (Berl); 2004 Apr; 173(1-2):175-85. PubMed ID: 14726995
[TBL] [Abstract][Full Text] [Related]
18. Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex.
Lacroix LP; Hows ME; Shah AJ; Hagan JJ; Heidbreder CA
Neuropsychopharmacology; 2003 May; 28(5):839-49. PubMed ID: 12637956
[TBL] [Abstract][Full Text] [Related]
19. Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus.
Engleman EA; Robertson DW; Thompson DC; Perry KW; Wong DT
J Neurochem; 1996 Feb; 66(2):599-603. PubMed ID: 8592129
[TBL] [Abstract][Full Text] [Related]
20. Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases.
Lacroix LP; Ceolin L; Zocchi A; Varnier G; Garzotti M; Curcuruto O; Heidbreder CA
J Neurosci Methods; 2006 Oct; 157(1):25-31. PubMed ID: 16697046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
